An object of the present invention is to provide a cell population comprising adherent cells having low differentiation capacity derived from a fetal appendage, methods for producing or using the same, and a pharmaceutical composition comprising the cell population, in particular wherein the proportion of CD73- and CD90-positive adherent cells derived from a fetal appendage is 90% or more; and the cell population satisfies a relative expression level of LFA-3 gene to the expression level of SDHA gene of 1.0 or more, in particular wherein the relative expression level of HAPLN1 gene to the expression level of SDHA gene is 4.0 or more and/or the relative expression level of CCND2 gene to the expression level of SDHA gene is 1.5 or less, in particular wherein the proportion of the STRO-1-negative adherent cells derived from a fetal appendage is 95% or more.

Provided are a composition and a sheet, including a mesenchymal stem cells-hydrogel-biodegradable support or a mesenchymal stem cells-hydrogel-nondegradable support and a preparing method thereof. More specifically, in the sheet including a mesenchymal stem cells-hydrogel-biodegradable support or a mesenchymal stem cells-hydrogel-nondegradable support according to the present invention, the high-active mesenchymal stem cells may be applied to a wounded part of a patient with epidermolysis bullosa as it is without isolation using proteases, and in the culturing, an extracellular matrix such as collagen, laminin, fibronectin, and elastin secreted from the mesenchymal stem cells is wholly present on the hydrogel to have an advantageous effect that skin reproduction and re-epithelization abilities are significantly excellent as compared with conventional dressing agents used for epidermolysis bullosa.

Provided are a composition and a sheet, including a mesenchymal stem cells-hydrogel-biodegradable support or a mesenchymal stem cells-hydrogel-nondegradable support and a preparing method thereof. More specifically, in the sheet including a mesenchymal stem cells-hydrogel-biodegradable support or a mesenchymal stem cells-hydrogel-nondegradable support according to the present invention, the high-active mesenchymal stem cells may be applied to a wounded part of a patient with epidermolysis bullosa as it is without isolation using proteases, and in the culturing, an extracellular matrix such as collagen, laminin, fibronectin, and elastin secreted from the mesenchymal stem cells is wholly present on the hydrogel to have an advantageous effect that skin reproduction and re-epithelization abilities are significantly excellent as compared with conventional dressing agents used for epidermolysis bullosa.

The present invention provides compositions of soy protein gel fibers, soy protein fiber membranes, and soy protein films. The present invention also provides methods of making the soy protein compositions and also uses of the compositions.

The present invention provides compositions useful in reducing, ameliorating, and/or preventing pain in a subject in need thereof. In one embodiment, the compositions comprise a halogenated volatile compound. The present invention further includes a method of reducing, ameliorating, and/or preventing pain in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of a composition of the invention. Dosing regimens contemplated within the invention include one-time administration, continuous administration, or periodic administration.

The present invention provides compositions useful in reducing, ameliorating, and/or preventing pain in a subject in need thereof. In one embodiment, the compositions comprise a halogenated volatile compound. The present invention further includes a method of reducing, ameliorating, and/or preventing pain in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of a composition of the invention. Dosing regimens contemplated within the invention include one-time administration, continuous administration, or periodic administration.

A portable transdermal administration patch apparatus comprises a communication control device and a pharmaceutical device which is fixed to and arranged at a lower end of the communication control device and electrically connected to the communication control device. The communication control device is formed of a micro-battery, a wireless control device and a micro-controller which are electrically connected. The preparation of the patch apparatus is achieved by: the preparation of medicinal patches and non-medicinal patches, the mounting of electrodes, interfacing with a micro-controller, and the communication control system, and starting administration. The transdermal apparatus is wearable and can be remotely controlled, and is convenient for administration, in particular, for the situations of daily administration for elderly patients with chronic illness and when there are a larger number of admitted inpatients, where a nurse can pre-set the administration time and dose, thus saving time and efforts of medical staff.

A kit for enabling delivery of an active compound to the skin for penetration into the skin, a delivery device for delivering an active compound, and a method of delivery of an active compound are provided. An active compound delivery kit for enabling delivery of an active compound into the skin of a subject includes an arrangement for providing a pathway into a biological barrier of a subject in an application zone, an active compound provided in dry form, and a delivery device for delivery of dissolved active compound to the application zone. Provision of a pathway into the biological barrier, preferably skin, is provided and the active compound applied in optimum form within a short time frame after forming the pathway ensuring treatment of the desired skin cells is optimised.

The invention provides a topical o/w emulsion which moisturizes, and protects, repairs or restores the skin lipid barrier of a mammal. The topical o/w emulsion composition comprises: a) a discontinuous oil phase; b) a continuous aqueous phase comprising water; c) a thickening agent; d) at least one lamellar membrane structure comprising (i) a phospholipid, (ii) a fatty alcohol, and (iii) a fatty acid; e) a pharmaceutically acceptable active agent; and f) optionally a dermatologically acceptable excipient. In one embodiment, the composition, in use, has a water vapor transmission rate of less than or about 75 g.Math.m.sup.−2.Math.hr.sup.−1 measured in vitro using the modWVTR test methodology.

A patch preparation which can produce the effect for preventing any problems due to the misuse of the patch preparation, includes a support and a plaster wherein the plaster includes a) an aliphatic compound with hydrophilic group which is in solid state at room temperature, b) a non-aqueous adhesive, and c) a solvent with a vapor pressure of 1 kPa or more at 20° C.